Adenosine
| Adenosine |
|---|
| ADENOCARD®, ADENOSCAN® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Adenosine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Synonyms / Brand Names: ADENOCARD®, ADENOSCAN®
Overview
Adenosine (ADO) is a purine nucleoside comprising a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond.
Adenosine plays an important role in biochemical processes, such as energy transfer — as adenosine triphosphate (ATP) and adenosine diphosphate (ADP) — as well as in signal transduction as cyclic adenosine monophosphate, cAMP. It is also an inhibitory neurotransmitter, believed to play a role in promoting sleep and suppressing arousal.
Adenosine also plays a role in regulation of blood flow to various organs through vasodilation.[1][2][3]
Category
FDA Package Insert[4]
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
References
- ↑ Sato, A; Terata, K; Miura, H; Toyama, K; Loberiza FR, Jr; Hatoum, OA; Saito, T; Sakuma, I; Gutterman, DD (April 2005). "Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease". American journal of physiology. Heart and circulatory physiology. 288 (4): H1633–40. doi:10.1152/ajpheart.00575.2004. PMID 15772334.
- ↑ Costa, F; Biaggioni, I (May 1998). "Role of nitric oxide in adenosine-induced vasodilation in humans". Hypertension. 31 (5): 1061–4. doi:10.1161/01.HYP.31.5.1061. PMID 9576114.
- ↑ Morgan, JM; McCormack, DG; Griffiths, MJ; Morgan, CJ; Barnes, PJ; Evans, TW (September 1991). "Adenosine as a vasodilator in primary pulmonary hypertension". Circulation. 84 (3): 1145–9. doi:10.1161/01.CIR.84.3.1145. PMID 1884445.
- ↑ "ADENOCARD (ADENOSINE) SOLUTION [ASTELLAS PHARMA US, INC.]".